The FDA has granted a de novo clearance to a wearable device—with a form factor you’re familiar with—that can check patients ...

New research indicates that 1 hour of moderate exercise per week can help prevent atrial fibrillation (AFib). While a small ...

OMRON Healthcare has received de novo authorization from the U.S. Food and Drug Administration (FDA) to market new home blood pressure monitors featuring AI-powered atrial fibrillation ...

The REACT-AF trial began in July 2023 and is led by researchers at Johns Hopkins Medicine. Randomized patients (half of the ...

Exposure to extreme heat may double or triple the risk of irregular heart rhythms in people with implanted defibrillators, ...

New research finds that on extremely hot days, people with implanted defibrillators face nearly triple the odds for a ...

Boston Scientific expects to complete enrollment in the coming months in the study comparing pulsed field ablation to ...

Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the third quarter and year-to-date of 2024. Recent Highlights: Third quarter revenue from Continuing Operations ...

Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy.

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Milestone Pharmaceuticals (MIST – Research ...

Boston Scientific is resuming its "Avant Guard" study of pulse field ablation (PFA) as a first-line therapy for atrial ...